Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Go back to Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)| AbbVie (NYSE: ABBV) | Delayed: 248.78 -7.68 (2.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $256.46 | 52 Week High | $68.12 | |||
| Open | $251.84 | 52 Week Low | $50.71 | |||
| Day High | $254.62 | P/E | 53.97 | |||
| Day Low | $248.41 | EPS | $4.61 | |||
| Volume | 5,572,036 | |||||
| (NASDAQ: GMAB) | Delayed: 33.53 -0.07 (0.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $33.60 | 52 Week High | $ | |||
| Open | $33.71 | 52 Week Low | $ | |||
| Day High | $33.84 | P/E | N/A | |||
| Day Low | $33.36 | EPS | $ | |||
| Volume | 1,550,685 | |||||
